Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

Trial Details

NCT ID

NCT07640295

Phase

PHASE1 / PHASE2

Sponsor

Jacobio Pharmaceuticals Co., Ltd.

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

• JAB-23E73 tablet，nab-paclitaxel，gemcitabine

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Hangzhou, Zhejiang, China|30.29365,120.16142
• Beijing, China|39.9075,116.39723
• Changsha, China|28.19874,112.97087
• Harbin, China|45.75,126.65

Key Eligibility Criteria

• Written informed consent signed by the participant or the participant's legally authorized representative must be obtained prior to performing any …
• 3\. No prior systemic antitumor therapy for advanced disease (treatment-naïve). 4. Presence of KRAS gene alterations: be enrolled upon approval by …
• 5\. ECOG performance status score of 0 or 1. 6. Adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.